BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response. OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management. METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.gov and abstracts recently presented at international congresses. RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.

New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors / DE FELICE, Francesca; Musio, Daniela; Cassese, Raffaele; Gravina, GIOVANNI LUCA; Tombolini, Vincenzo. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 17:3(2017), pp. 282-289. [10.2174/1568009616666160813183738]

New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors

DE FELICE, FRANCESCA
Primo
;
CASSESE, RAFFAELE;GRAVINA, GIOVANNI LUCA
Penultimo
;
TOMBOLINI, Vincenzo
Ultimo
2017

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response. OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management. METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials.gov and abstracts recently presented at international congresses. RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM.
2017
immunotherapy; glioblastoma multiforme; check-point; radiotherapy; PD-1; CTLA-4; ipilimumab
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors / DE FELICE, Francesca; Musio, Daniela; Cassese, Raffaele; Gravina, GIOVANNI LUCA; Tombolini, Vincenzo. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 17:3(2017), pp. 282-289. [10.2174/1568009616666160813183738]
File allegati a questo prodotto
File Dimensione Formato  
De Felice_New_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4.14 MB
Formato Adobe PDF
4.14 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/878529
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
social impact